Oncternal Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Oncternal Therapeutics

03/05/2023 03:02

* Oncternal Therapeutics Inc  ONCT.OQ   ONCT.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 4. 
    * The San Diego California-based  company is expected to
report  a
77.7% decrease in revenue to $166.67 thousand from $746 thousand
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Oncternal
Therapeutics
Inc is for a loss of 20 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 5
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.8%
in the last three months. ​
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $1.9​, above​ its last closing price
of $0.34. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.20       -0.21      -0.20     Beat    4
 Sep. 30 2022  -0.24       -0.24      -0.21     Beat    11.3
 Jun. 30 2022  -0.22       -0.23      -0.23     Met     -0.7​
 Mar. 31 2022  -0.20       -0.20      -0.20     Met     1.2
 ​​Dec.        -0.24       -0.25      -0.16     Beat    35
 31 2021                                                
 Sep. 30 2021  -0.20       -0.16      -0.19     Missed  -18.7​
 Jun. 30 2021  -0.14       -0.14      -0.16     Missed  -16.4
 Mar. 31 2021  -0.10       -0.10      -0.12     Missed  -20
 This summary was machine generated May 3 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated